Alzheimer's disease is a progressive neurodegenerative brain disorder that gradually destroys memory, thinking skills, and eventually the ability to perform daily tasks.
Longeveron appoints Nirav Jhaveri as CFO, succeeding Marie Washburn. The company anticipates Phase 2b trial results for laromestrocel in HLHS in September, with FDA guidance that a successful trial would be pivotal for BLA filing.
Silo Pharma received a European patent grant and a Japan patent allowance for SPC-15, its intranasal PTSD prevention candidate. The patents cover methods using serotonin 4 receptor agonists to prevent stress-induced psychiatric disorders.
Alpha-synuclein biomarkers in saliva, skin, and CSF show diagnostic promise for Parkinson's disease, with seed amplification assays demonstrating high sensitivity and specificity. Salivary gland biopsies and oral brushings are being studied as less invasive detection methods, though clinical implementation still faces challenges.
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
New 3D brain tissue models, laser imaging, and organoid sensors aim to speed drug development for Alzheimer’s and other neurological diseases. The LMU model replicates Alzheimer’s aggregates, MIT’s laser images the blood-brain barrier at record speed, and UNC’s sensor records neural activity without damaging organoids.
FDA approved a subcutaneous starting dose of Leqembi for early Alzheimer's disease. AAIC 2026 real-world data showed most patients stable or improved; a mouse study found KCL-286 repaired DNA damage and reduced inflammation.
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
Prothena Corporation plc will report its second quarter and first six months of 2026 financial results on August 6, 2026, after U.S. market close. No conference call will be held, consistent with past practice. The company focuses on neurodegenerative and rare amyloid diseases.
An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780383 |
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration |
NOT_YET_RECRUITING | PHASE1 |
| NCT07779863 |
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease |
NOT_YET_RECRUITING | NA |
| NCT07775625 |
Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music |
RECRUITING | NA |
| NCT07758595 |
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease |
RECRUITING | PHASE1 |
| NCT07752784 |
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD. |
RECRUITING | PHASE3 |
| NCT07723950 |
A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease |
NOT_YET_RECRUITING | |
| NCT07721467 |
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin |
NOT_YET_RECRUITING | PHASE2 |
| NCT07717411 |
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07688213 |
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease |
RECRUITING | PHASE2 |
| NCT07658430 |
Deep Cervical Lymphovenous Anastomosis for Moderate Alzheimer's Disease |
NOT_YET_RECRUITING | NA |
